



November 12, 2015

Gene Techno Science Co., Ltd.

Code: 4584 (TSE Mothers)

President

Masanari Kawaminami

Announcement of signing of Memorandum of Understanding with
Senju Pharmaceutical Co., Ltd. regarding Collaboration for a
Biosimilar Product in the Ophthalmology Field

Gene Techno Science Co., Ltd. (“GTS”) announced the execution of the above-mentioned Memorandum of Understanding (“MOU”) with Senju Pharmaceutical Co., Ltd. (“Senju”), regarding the joint development to obtain a regulatory approval and sales of Japanese market for a biosimilar product in the ophthalmology field (“Product”). With this MOU, Senju will obtain a certain number of GTS stock share and will establish robust partnership between Senju and GTS through capital alliance.

1. Background of Collaboration

GTS had developed and, at present, manufactures the active pharmaceutical ingredient (“API”) of a filgrastim biosimilar product which obtained, for the first time under the Japanese Biosimilar Guideline, the regulatory approval. As GTS strives to be the leading company in the field of biosimilar business, GTS is actively developing several biosimilar products.

Senju is a distinguished pharmaceutical company specialized in ophthalmology and otolaryngology field and has high expertise and deep experience on both ethical and OTC products. Therefore, Senju is an ideal partner for GTS to develop, obtain a regulatory approval and sell the Product in Japan.

Recently, GTS has made enough progress in the development for a manufacturing method of the API and scale-up of the Product for further development, and Senju appreciates GTS’s proven activities and also promising market of the Product. For these reasons, Senju and GTS agreed to enter into the MOU. Detailed terms and conditions of the collaboration, including without limitation to sharing of costs and responsibility for tasks in the collaboration, will be diligently discussed between Senju and GTS. Execution of the agreement is expected to be done by March 2016 at the latest. In addition, Senju and GTS agreed on capital alliance in order to strengthen

the mutual relationship.

2. Content of Collaboration

2-1) Business collaboration

Under the MOU, both companies will work together to decide an optimized scheme, including business plan, role and responsibility and cost share, in order to surely make the Product available to the patients.

2-2) Capital alliance

Whiz Partners Inc. (“Whiz Partners”) is the unlimited partner of Whiz Healthcare PE1 Limited Partnership (“Whiz Healthcare”), which entered into an Investment Agreement with GTS in February 2013 and has fully supported GTS in business development, alliance activities and so on for the purpose of increasing the value of GTS.

Under the circumstance, Whiz Partners discussed with Senju and GTS an investment arrangement and Senju agreed to purchase 138,800 GTS’s shares from Whiz Healthcare. At the same time, Whiz Healthcare will exercise its 13 stock acquisition rights (137,709 shares) of its 2nd Stock Acquisition Rights issued on May 1, 2013.

GTS will receive 260 million Japanese Yen in return and plans to spend it for the research and development of the Product.

3. Others

The influence of the execution of the MOU on the operating performance of the fiscal year 2015, ending March 2016 is announced today in “Announcement of Revision of the Operational Guideline”.

When the Agreement is entered into between the companies, the fact will be announced promptly.

Media Contact:

E-mail: info@g-gts.com

Masaki Okusawa

Tel: +81-3-3517-1353